Clinical characteristics at initiation of bDMARD
|
Positivity of RF, n
|
16 (84.2)
|
18 (85.7)
|
0.89
|
Positivity of ACPA, n
|
18 (94.7)
|
19 (90.5)
|
0.61
|
DAS28-ESR
|
4.76 (3.99–5.15)
|
4.02 (3.60–5.09)
|
0.26
|
SDAI
|
19.6 (15.2–26.1)
|
14.7 (11.1–24.6)
|
0.19
|
CDAI
|
18 (13.5–24.5)
|
14.4 (11.0–20.8)
|
0.28
|
Clinical characteristics at discontinuation of bDMARD
|
Age, years
|
55 (46–61)
|
53 (41–61)
|
0.95
|
Female sex
|
14 (73.7)
|
19 (86.4)
|
0.16
|
Duration of disease, years
|
5.0 (1.4–8.0)
|
3.0 (2.0–4.0)
|
0.54
|
Positivity of RF, n
|
11 (64.7)
|
12 (57.1)
|
0.74
|
bDMARD use, n
|
IFX, 8; ADA, 5; CZP, 1; ETN, 2; TCZ, 2; ABT, 1
|
IFX, 6; ADA, 2; GLM, 4; CZP, 1; ETN, 1; TCZ, 5; ABT, 2
| |
TNF inhibitor use, n
|
16 (84.2)
|
14 (66.7)
|
0.20
|
Concomitant MTX, n
|
17 (89.5)
|
16 (76.2)
|
0.27
|
Duration of bDMARD therapy, months
|
12 (10–23)
|
12 (10–21)
|
0.75
|
Duration until clinical remission, months
|
3 (1–5)
|
3 (2–4)
|
0.95
|
Duration of clinical remission, months
|
8 (7–16)
|
9 (6–12)
|
0.80
|
Tender joint counts, n/28 joints
|
0 (0)
|
0 (0)
|
0.33
|
Swollen joint counts, n/28 joints
|
0 (0)
|
0 (0)
|
0.61
|
PtGA, mm
|
3 (2–7)
|
4 (2–8)
|
0.62
|
EGA, mm
|
3 (2–4)
|
4 (2–5)
|
0.39
|
CRP, mg/dl
|
0.05 (0.03–0.05)
|
0.05 (0.05–0.09)
|
0.41
|
ESR, mm/h
|
11 (8–15)
|
7 (5–14)
|
0.44
|
MMP-3, ng/ml
|
35 (26–58)
|
33 (28–49)
|
0.77
|
DAS28-ESR
|
1.73 (1.29–2.01)
|
1.57 (1.20–2.02)
|
0.76
|
SDAI
|
0.9 (0.5–1.2)
|
0.8 (0.5–3.0)
|
0.58
|
CDAI
|
0.8 (0.5–1.1)
|
0.7 (0.4–2.7)
|
0.62
|
HAQ-DI
|
0 (0–0.1)
|
0 (0)
|
0.67
|
Ultrasound findings
|
Positivity of GS, n
|
10 (52.6)
|
14 (66.7)
|
0.37
|
Total GS score
|
2 (0–4)
|
2 (0–4)
|
0.65
|
Positivity of PD, n
|
5 (26.3)
|
3 (14.3)
|
0.34
|
Total PD score
|
0 (0)
|
0 (0)
|
0.45
|
Positivity of bone erosion, n
|
10 (52.6)
|
3 (14.3)
|
0.01
|